CD56 marks human dendritic cell subsets with cytotoxic potential.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

1. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment.PloS one · 2016
   Trial
2. Revealing the effects of various immune cells in anorexia nervosa: Evidence from Mendelian randomization.Medicine · 2025
   Article
3. Resident Synovial Macrophages in Synovial Fluid: Implications for Immunoregulation in Infectious and Inflammatory Arthritis.bioRxiv : the preprint server for biology · 2024
   Article
4. A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease.Blood · 2023
   Article
5. Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated byFrontiers in immunology · 2022
   Article
6. CD56 regulates human NK cell cytotoxicity through Pyk2.eLife · 2020
   Article
7. Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset.Frontiers in immunology · 2020
   Article
8. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56.Nature communications · 2019
   Article
9. CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15.Cancers · 2019
   Article
10. CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse.Scientific reports · 2019
    Article
11. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.Frontiers in immunology · 2019
    Review
12. GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance.International journal of molecular sciences · 2018
    Review
13. CD56 in the Immune System: More Than a Marker for Cytotoxicity?Frontiers in immunology · 2017
    Review
14. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.Journal of hematology & oncology · 2016
    Article
15. Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.PloS one · 2015
    Article
16. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells.Journal of cellular and molecular medicine · 2014
    Article
17. Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2013
    Review
18. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.Human vaccines & immunotherapeutics · 2013
    Review
19. Interferon α may be back on track to treat acute myeloid leukemia.Oncoimmunology · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 3 institutions in 4 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as